IgA Nephropathy
Conditions
Interventions
Arm A: LNP023
Arm B: Placebo
Sponsors
Maruyama Hideki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Male and female patients >= 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows: - For patients eGFR >= 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required. - For patients with eGFR 30 to =1 g/g (113 mg/mmol) sampled from FMV or 24h urine collection, as well as at the completion of the run-in period by UPCR >=1 g/g (113 mg/mmol) calculated as the mean of two 24h urine collections obtained within 14 days of each other at baseline. - Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated. - If not previously vaccinated, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated. - All patients must have been on supportive care including stable dose regimen of ACEi or ARB at either the locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgment) for at least 90 days before first study drug administration. In addition, if patients are taking diuretics or other antihypertensive therapy, the doses should also be stabilized for at least 90 days prior to the first dosing of study treatment.
Exclusion criteria
Exclusion criteria: - Any secondary IgAN as defined by the investigator; secondary IgAN can be associated with cirrhosis, celiac disease, Human Immunodeficiency Virus (HIV) infection, herpetiformis, seronegative arthritis, small-cell carcinoma, lymphoma, disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease, familial mediterranean fever, etc. - Sitting office SBP >140 mmHg or DBP >90 mmHg at the randomization visit - Patients previously treated with immunosuppressive or other immunmodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, hydroxychloroquine, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (>10 mg/d prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to first study drug administration - Prior use of LNP023 or prior enrollment in any other LNP023 clinical trial where study drug was taken, including matching placebo - History of recurrent invasive infections caused by encapsulated organisms, such as meningococcus and pneumococcus. - Active systemic bacterial, viral (including COVID-19) or fungal infection within 14 days prior to study drug administration. Other protocol-defined inclusion/exclusion criteria may apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Ratio to baseline in Urine Protein to Creatinine Ratio(sampled from 24h urine collection) at 9 months (Time Frame:Baseline and 9 months) - Evaluated at interim analysis - To demonstrate superiority of LNP023 vs. placebo in the change of proteinuria at 9 months by measuring Urine Protein to Creatinine Ratio sampled from a 24 h urine Collection. - Annualized total Estimated Glomerular Filtration Rate(eGFR) slope estimated over 24 months).(Time Frame:Baseline and 24 months) - Evaluated at fhe final analysis - To demonstrate superiority of LNP023 vs. placebo in slowing renal disease progression measured by the annualized total slope of Estimated Glomerular Filtration Rate(eGFR) change over 24 months. | — |
Countries
Argentina, Australia, Belgium, Brazil, Canada, China, Colombia, CZE, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Norway, Russia, Singapore, Spain, Sweden, Taiwan, Thailand, Turkey, UK, US
Contacts
Public ContactHideki Maruyama
Novartis Pharma. K.K.
Outcome results
None listed